Partnering

Our approach

Partnerships and collaborations are in our DNA — from academic and clinical researchers to global biopharmaceutical companies. We understand that the best science and the best medicines only advance when the right people and organizations work together to leverage their collective expertise. We are proud of our record of collaborations with world-class biopharmaceutical companies, as well as leading research institutions. The Company’s success establishing and growing these relationships is a reflection of our strong scientific acumen and strategic vision.

Establishing a network of agreements and collaborations with academic laboratories, clinical centers and industrial leaders is at the heart of Innate Pharma’s strategy. We are constantly looking for opportunities of collaboration in the field of antibodies in immuno-oncology.

Our partnerships opportunities

Partnerships are and continue to be accelerators for our research and development pipeline, providing us with access to innovation, indication expertise and non-dilutive capital as well as the ability to expand our reach into areas beyond our core focus.

We continue to look for industry partners that can help support the development of our product candidates in immuno-oncology.

Beside a pipeline of innovative proprietary products, we have also developed proprietary antibody technologies, such as ANKET^® , our NK cell engager platform, and site-specific conjugation that could be used to create new anti-cancer therapeutics and are available for partnership opportunities.

We are looking for partners with resources complementary to ours such as strong clinical capacity to support broad clinical development programs as well as manufacturing and large commercialization capabilities. 

Thus, in order to develop our product pipeline or technologies, we are always looking for partners to establish research collaborations, co-development and license agreements, in oncology and inflammation.